Reproductive outcome in women with body weight disturbances

Similar documents
Achieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center

Polycystic ovarian syndrome Can lifestyle modifications help?? Dr Saloni Assistant Professor, Deptt of OBG BPSGMC for Women, Khanpur Kalan

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

Polycystic Ovarian Syndrome (PCOS) LOGO

Polycystic Ovary Syndrome

Pregnancy outcome in women with polycystic ovary syndrome

DOES INSULIN RESISTANCE CAUSE HYPERANDROGENEMIA OR HYPERANDROGENEMIA CAUSES INSULIN RESISTANCE IN PCOS

Richard S. Legro, M.D., Penn State College of Medicine, Dept of Ob/Gyn, Hershey, PA, USA

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

S. AMH in PCOS Research Insights beyond a Diagnostic Marker

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview

Metformin in early pregnancy and abortions. Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland

CREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University

WEIGHT GAIN DURING MENOPAUSE EMERGING RESEARCH

Infertility for the Primary Care Provider

Infertility: A Generalist s Perspective

IMPACT OF NUTRITION ON GYNECOLOGICAL HEALTH OF FEMALE ADOLESCENTS

The Impact of Insulin Resistance on Long-Term Health in PCOS

clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology


The Pharmacology of PCOS

SAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome

Gestational Diabetes. Gestational Diabetes:

PCOS and Obesity DUB is better treated by OCPs

Objectives 06/21/18 STILL A PLACE FOR PILLS DON T IVF EVERYTHING. Clomiphene citrate and Letrozole. Infertility Case Studies. Unexplained Infertility

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks

Original Article Pregnancy Complications - Consequence of Polycystic Ovary Syndrome or Body Mass Index?

Endocrinology of the Female Reproductive Axis

Female Reproductive System. Lesson 10

Diabetic Medicine. Myo-inositol may prevent gestational diabetes in PCOS women. Preliminary data.

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

Polycystic Ovary Syndrome (PCOS):

METABOLIC SYNDROME IN REPRODUCTIVE FEMALES

Nature and Science 2017;15(8)

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation

Rotterdam Criteria 9/30/2017. A Changing Paradigm in PCOS. Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause?

Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?

Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai

Vishwanath Pattan Endocrinology Wyoming Medical Center

Assisted Reproductive. Technologies: Present and. Future

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016

Hypothalamic Amenorrhea: To Treat or Not to Treat with Estrogen Replacement. Hypothalamic amenorrhea NASPAG ACRM 2015

Reproductive FSH. Analyte Information

Outline. Diagnos(c Criteria and PCOS features Diagnos(c Criteria by age Reproduc(ve Care for the woman with PCOS, a focus on fer(lity and pregnancy.

3. Metformin therapy for PCOS

PCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS

Overview of Reproductive Endocrinology

Role of inositol in Reproductive Function

PCOS & Diet Therapy. Dr. Ladan Giahi Immunonutritionist Avicenna Research Institute October 2015

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)

Metabolic changes in menopausal transition

The New GDM Screening Guidelines. Jennifer Klinke MD, FRCPC Endocrinologist and Co director RCH Diabetes in Pregnancy Program

WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?

Amenorrhoea: polycystic ovary syndrome


Gonadotrophin treatment in patients with Polycystic Ovary Syndrome

Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study

Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome

Hyperandrogenism. Dr Jack Biko. MB. BCh (Wits), MMED O & G (Pret), FCOG (SA), Dip Advanced Endoscopic Surgery(Kiel, Germany)

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF

CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME

The menstrual cycle. François Pralong

The menstrual Cycle. François Pralong

Update on PCOS Research. Richard S. Legro, M.D., Penn State College of Medicine, Dept of Ob/Gyn, Hershey, PA, USA

The Effects of Exercise and Nutritional Counseling. in Women with Polycystic Ovary Syndrome. A Thesis Submitted to the College of

Management of Pregestational and Gestational Diabetes Mellitus

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome

The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69

IVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman

Polycystic Ovary Syndrome

Leptin levels and menstrual function in HIV-infected women in rural India

JMSCR Vol 07 Issue 01 Page January 2019

PCOS. pregnancy complications. Prof. Bart CJM Fauser. Dept. Reproductive Medicine and Gynecology. University Medical Center, Utrecht, The Netherlands

Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary

Approach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD

Diagnosis and Management of Polycystic Ovary Syndrome During Adolescence: Questions and Controversies

Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study

Abstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online; on web 15 November 2004

PCOS What s new in Diagnosis & Treatment?

The Players. Liver Thyroid Adrenals Pancreas Reproductive System Pituitary Gut Bacteria

Jannet Huang, MD, FRCPC, FACE, ABIHM, CCD, NCMP.

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome

Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.

I. Endocrine System & Hormones Figure 1: Human Endocrine System

Clinical Profile Polycystic Ovarian Syndrome Cases

2/13/2018. Update on Gestational Diabetes. Disclosure. Objectives. I have no financial conflicts of interest.

Test Briefing on Hormonal Disorders and Infertility


BACKGROUNDER. Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive

Obesity and Fertility in Women: Can we and should we treat obesity prior to conception?

Addressing Practice Gaps in PCOS

UPDATE: Women s Health Issues

Reproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives

Reproductive Health and Pituitary Disease

A Tale of Three Hormones: hcg, Progesterone and AMH

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS)

Transcription:

Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel

Weight Status BMI (kg/m 2 ) Underweight <18.5 Normal weight 18.5-24.9 Overweight 25.0-29.9 Obese >30.0 WHI report 1997 NIH, 1998

Healthy range of body fat Age 25-39 Women (%) 21-32 Men (%) 8-19 40-59 23-33 11-21 >60 24-35 13-24

Body Fat Essential Fat Bone marrow Organs Central nerve system Muscles Storage Energy Women 12% of TBW Men 3% of TBW Breast, pelvis, hips, thighs (Pregnancy requires >50,000 calories over normal metabolic requirements. Lactation >500-1000 Cal/day)

Reproductive performance

The overweight male Reproductive function is satisfactory Normal semen analysis Libido BMI Testrosterone Test. Treat. Visceral fat Improve insulin sensitivity

How low is too low for body fat percentage in women? How Much Body Fat Do We Need? Critical body weight of 47 kg is required for onset of cyclical ovarian activity. Frisch & McArthur Science 1974:185;949-51 Frisch Hum. Reprod. 1987:2;521-33

A women must have a minimum of 13-17% of body fat for regular menstruation Human ovarian function is extremely vulnerable to an energy imbalance Luteal phase suppression Follicular phase suppression Ovulatory failure Oligomenorrhea Amenorrhea Ellison, Am Anthropol 1990:2;933-52

About 1 5% of women suffer from weight-related amenorrhea Laughlin et al. J. Clin. Endocrinol. Metab. 1998:88;25-32 Indirect mechanism signals hypothalamus GnRH Temperature control Changes in energy metabolism

Obesity Environmental factors Genetic World epidemic with ever increasing incidence

Fat distribution Peripheral (Gynaecoid) Abdominal (Android)

Adipose tissue is a complex and highly active metabolic and endocrine organ White fat tissue Adipose tissue contains: Adipocytes Immune cells Connective tissue matrix Nerve tissue Stromovascular cells Brown fat tissue 60-85% lipid (90-99% is triglyceride). Heat regulation Body Cushioning Energy storage Rich vascularization Packed mitochondria Metabolic heat production without muscles contraction

Adipose tissue acts as an endocrine tissue Androgen Aromatase Estradiol Estrogen Esteron DHEA 17-bets hydroxysteroid dehydrogenase Androstendiol

Adipose tissue acts as an endocrine tissue Metabolites estrogen to 16-hydroxylated estrogen (high estrogen activity) Storage steroids hormone Stimulate insulin secretion Decrease liver production of SHBG allow high free levels of androgens Frisch, Sci Am, 1998;258:88-95

Polycystic Ovarian Syndrome Most common endocrine disorder in women of reproductive age Stein and Leventhal (1934) Affects 5-10% of the population Franks S, N Engl J Med 1995; 333:853-861 ~20% of infertile females Short and long-term consequences on general and reproductive health

Oligo-amenorrhea Hyper-androgenism Obesity and reproductive disturbances Overnourishment Overproduction of insulin Ovulation disruption

Abdominal obesity 10-50% PCOD Stein and Leventhal (1934) Obesity and reproductive disturbances Incidence 38-88% Syndrome O Overnourishment Overproduction of insulin Ovulation disruption

Prevalence of hyperinsulinemia and insulin resistance in PCOS In ~ 65% of obese PCOS women In ~ 20% of lean PCOS women Dale et al., Fertil Steril 1992; 58:487-91

Enhancement of pituitary LH pulse amplitude Obesity Hyperinsulinemia In PCOD patients Arrest of follicular development Free testosterone Suppress liver production of SHBG

PCOD Non-obese Obese LH GH LH and IGF-I Insulin resistance Hyperinsulinemia effect on theca cells IGFBP-I IGF-I Cytochrome Key enzyme p-450c 17-alpha activity Androgen secretion SHBG

How do we treat Infertility in Obese PCOD patients

Weight loss Loss of 5% of TBW Resumed ovulation in 90% Pregnancy in 45% >50% pregnancy per cycle Treatment 25% miscarriage compared with 75% for the same group Clark et al. Hum Reprod 1995;10:2705-12

Weight loss 69 Patients with BMI>30 Loss of 4 kg Resumed ovulation in 90% Pregnancy in 77.6% With & without Treatment Miscarriage rate - 75% before losing weigh and 18% after (p<0.01) Clark et al. Hum Reprod 1998;13:1502-5

7000 6000 Estradiol (pmol/l) 5000 4000 3000 2000 1000 0 P<0.01 Hyperins Normoins Basal -5-4 -3-2 -1 0 Days from hcg injection Fulghesu et al. J.C.E.M. 1997

7 Diameter >12 mm and < 16 mm 6 5 Number of follicles 4 3 2 1 P<0.01 Hyperins Normoins 0 Basal -5-4 -3-2 -1 0 Days from hcg injection Fulghesu et al. J.C.E.M. 1997

120 No. of Amps. 100 80 60 40 20 0 0 20 40 60 80 Fasting insulin levels R=0.6, p<0.003 Homburg et al. Hum Reprod 1996

No. of Amps. 120 100 80 60 40 20 0 0 10 20 30 40 BMI R=0.6, p<0.004 Homburg et al. Hum Reprod 1996

Metformin Dimethylbiguanide Multiple mechanisms of action: Inhibition of gluconeogenesis in the liver Enhanced peripheral uptake of glucose Increased intestinal use of glucose Decreased fatty acid oxidation

61women with BMI >28 USA Venezuela Italy PCOS 26 women received - Placebo 35 women received - Metformin 1500 mg/day 1 14 28 35 Prog. >25 nmol/l 1 ovulated 14 ovulated P<0.001 Nestler et al., New Engl J Med 1998

Effects of metformin on ovarian function and metabolic factors in PCOS Randomized double-blind blind placebo controlled trial Frequent blood sampling (twice weekly) 47 women received - Placebo 49 women received - Metformin 850 mg b.i.d. 14 weeks 13% ovulated 23% ovulated P<0.01 Fleming et al. JCEM 2002

Metformin dosing in obese women with PCOS 29<BMI<37 BMI>37 1000 mg/day or 1500 mg/day Significant weight reductions in all groups Higher dose not more effective Harborne and Fleming ASRM 2002 O-89

Complications during pregnancy

Meta-analysis of pregnancy outcome Early miscarriage Boomsma et al. Hum Reprod 2006;12:673 BMI 720 patients vs. 4505 controls Spon. Abor. Odds ratio <18.5 17% 0.94 18.5-24.9 18% 1.0 25-29.9 22% 1.29 30-34.9 27% 1.71 >35 31% 2.19

270 women, who were treated for infertility Pregnancy rate - 45.2%, live birth rate 37.8% Al-Azemi et al. Arch Gynecology 2003

Bellver et al. 2003

Obesity to Pregnancy-related Complications BMI >35 Preeclampsia (5 fold increase) Stillbirths after 28 weeks gestation (3 fold increase) Early neonatal death (3.5 fold increase) Large-for-gestational-age infants (4 fold increase) Cedergen MI, Obstet Gynecol 2004 A Swedish, population-based cohort study (n=805,275) Cnattingius et al NEJM 1998

Gestational diabetes General population 1-3% GDM Obese women 17% GDM Gabbe S. N Engl J Med 1986;315:1025

Long term metabolic consequences PCOS and risk of type II diabetes 10-20% type II diabetes (within 10 years) 35% Linne et al BJOG2002,109:1227

Delivery complications Rate of CS planned and acute 2 x higher Complications Blood loss Infection Dehiscence Hernia formation

Newborn complications During delivery Head trauma Shoulder dystocia Brachial plexus lesions Fractures of the clavicle

Newborn complications >30 BMI Birth defects Defect Odds ratio Spina bifida 3.5 Omphalocele 3.3 Heart defects 2.0 Multiple anomalies 2.0 Possible explanations hyperglycemia, elevated insulin, elevated estrogen Matgaret et al. Pediatrics 2005;111:1152

Impact of obesity on reproduction Condition Menstruation Infertility Miscarriage Associated risks Menstrual dysfunction: Amenorrhea, oligomenorrhea Anovulatory infertility, poor response to ovulatory drugs Increase risk Rich-Edwards et al AJOG 1994

Conclusions Any effort should be invested in education and understanding the complications of high BMI before and during pregnancy.